(1 - 21 von 21
)
Origenis GmbH Announces Global License and Collaboration ...
“We are excited to apply our technology platform as well as our interdisciplinary approach and chemical expertise to a novel class of compounds supporting Expansion in their efforts to develop medicines for RNA-mediated diseases,” Michael Almstetter, CEO of Origenis.
BIO CEO & Investor Conference | Biotechnolo Qwoted
app.qwoted.com
Mr. Michael Almstetter Ceo, Origenis Gmbh. Mr. Albert Gianchetti President and Ceo, Xylocor The…utics, Inc. Dr. Christopher J. Burns › event-bio...
News on kinase inhibitors - bionity.comwww.bionity.com › news › topic
www.bionity.com
Michael Almstetter, CEO and ... more. Watchlist. OCTIMET secures over EUR 11 million to develop its highly selective MET kinase inhibitors. 19-Jan
sortiert nach Relevanz / Datum